PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2024; 07(03): 112-117
DOI: 10.1055/s-0044-1787693
Review Article

Recent Perspectives on Impulse Control Disorder in Dopamine Agonist-Treated Patients in Endocrine Practice

Autor*innen

  • Khaled M. Aldahmani

    1   Division of Endocrinology, Tawam Hospital, SEHA, Al Ain, Abu Dhabi, United Arab Emirates
    2   Department of Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, Abu Dhabi, United Arab Emirates

  • Mussa H. AlMalki

    3   Department of Endocrinology, Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia
    4   College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

Dopamine agonists (DAs) are the primary treatment for patients with hyperprolactinemia. However, there are potential risks of impulse control disorders (ICDs), particularly in those with predisposing factors. Early recognition of ICDs is essential, as reducing the dose or discontinuing the medication often resolves the issue. In some cases, alternative treatments like surgery may be necessary, especially for microprolactinoma or intrasellar macroprolactinoma. Future research should focus on identifying confounding risk factors for ICD development, confirming the presence of ICDs with the help of psychiatrists, documenting the severity of ICDs, and providing guidance on optimal management strategies upon detection of ICDs. We here briefly review the frequencies, risk factors and provide practical guidance on identification and management of ICDs in the context of managing pituitary disorders.

Keywords

pituitary - dopamine agonist therapy - impulse control disorder - prolactinoma - hyperprolactinemia

Authors' Contribution

K.A. conceived the article's concept, coordinated its design, and performed the literature search. M.A. reviewed the data and edited the manuscript. Both authors read and approved the final manuscript.




Publikationsverlauf

Artikel online veröffentlicht:
29. Juli 2024

© 2024. Gulf Association of Endocrinology and Diabetes (GAED). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India